SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Elmer who wrote (1518)5/14/2003 7:25:38 PM
From: Miljenko Zuanic   of 3044
 
Elmer,

First I love when Rick first take shot. So, I can choose my words more carefully. <g> ļ

Dozen indicators suggest that V will be sinergistic with chemo, and play rule in solid tumor combination(s) therapy. One good indicator (from those who are in field) is investigators and NCI entuziazm visible by V cancer trials numbers and speed they are enrolling pts and completing trials. As I mentioned early, ASCO will help to better project (at this time it is hard) V utility in other cancer type (CC, NSCLC, PS, RCC, OC, ¡K).

Do I believe that V will work. Yes, I do. But, what I believe and what is real word can be like sky and land, far, far away.

One more thing. Usually drug that work for hematology cancer does not work as good in solid tumors. Velcade may be excluded, based on mode of action. It is and will be toxic to all cells, but IF one can show me one BROAD chemo agent without toxicity I will change my mind.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext